OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2024-12-31-accounts

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2024

COELIAC UK (A Company Limited by Guarantee)

Registered Charity Number: 1048167 Registered Company Number: 03068044 Scottish Charity Number: SC039804

Page 1

Annual Report and Financial Statements for the year ended 31 December 2024

Coeliac UK

Contents Page
Legal and administrative information 3-4
Structure, Governance and Management 5-8
Report of the Board of Trustees 9-21
Independent Auditors’ report 22-26
Consolidated statement of financial activities 27
Consolidated balance sheet 28
Consolidated statement of cash flows 29
Notes to the financial statements 30-45

Page 2

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2024

The organisation is a charitable company limited by guarantee, incorporated on 14 June 1995 and registered as a UK Charity on 20 July 1995. Coeliac UK is the successor organisation to The Coeliac Society which was established in 1968.

The Charity is governed by its Articles of Association which set out its objects and powers.

The Articles provide for the Board to consist of up to nine elected Trustees, two co-opted Trustees and one Trustee nominated by the Health Advisory Council. A trustee shall hold office for a period of 3 years and shall then be subject to reelection and may be re-elected for a further term of 3 years after which they must retire as a Trustee but may be re-elected as a Trustee after an intervening period of at least 1 year.

Board of Trustees Lawrence Broadie Sarah Bull (Co-opted 07/11/2024) Maureen Burnside – Chair (until 22/02/2024 – Resigned 15/06/2024) Anne Davis Kate Denham Chris Dilloway – Chair (from 22/02/2024) Aishah Farooq Nuala Gallagher (Co-opted 20/02/2025) Clive Hart Dr Anita Patel Professor Alan Perkins (Resigned 15/06/2024) Dr Gerry Robins Miranda Sheffield Nicola Valmas

Company Secretary Ashley Bailey (Appointed 22/02/2024 – Resigned 20/02/2025) Sally Malthouse (Appointed 20/02/2025) Chief Executive Hilary Croft Company Number 03068044 Charity Number 1048167 Scottish Charity Number SC039804 Registered office address Artisan Hillbottom High Wycombe Buckinghamshire HP12 4HJ

Page 3

Annual Report and Financial Statements for the year ended 31 December 2024

Coeliac UK

Auditors Moore Kinston Smith LLP
9 Appold Street
London
EC2A 2AP
Bankers HSBC Bank plc
Oxford Circus Branch
196 Oxford Street
London
W1D 1NT
Lloyds Bank plc
21-31 White Hart Street
High Wycombe
Buckinghamshire
HP11 2HL
Investment Manager Cazenove Capital
1 London Wall Place
London
EC2Y 5AU
Solicitors Blaser Mills
Park House
40 Oxford Road
High Wycombe
Buckinghamshire
HP11 2EE

Page 4

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2024

The Charity

Structure, Governance and Management

Coeliac UK is a charitable company limited by guarantee, incorporated on 14 June 1995, and registered as a Charity on 20 July 1995 with the Charity Commission. It was also registered with the Office of the Scottish Charity Regulator in 2008.

The Charity’s objectives are set out in its Articles of Association adopted on 3rd July 2021:

Public Benefit

The Trustees, in exercising their powers and duties, have complied with their duty in Section 17 of the Charity Act 2011 to have due regard to the public benefit guidance published by the Charity Commission. In preparing the report and accounts, the Trustees complied with the requirements in that guidance to report on the significant activities and achievements of the Charity in 2024. They have reported in a way that both sets out the aims and strategies of the Charity and demonstrates how the aims and activities of the Charity were carried out for the public benefit.

Management and Staff

The Board of Trustees delegates the day-to-day management of the Charity to the Chief Executive who led a team of approximately 52 full time equivalent staff in 2024. Their work is supplemented at times of peak workload by a limited number of temporary staff. The staff work within the Delegation of Authority agreed by the Board. The staff agree a work plan with the Board at the beginning of the year and report progress at Board meetings throughout the year, with regular reporting.

The Board of Trustees appoints an HR Committee to oversee the setting of pay and remuneration for senior management and the entire organisation. Their remit is to regularly review and agree performance review arrangements; agree remuneration policies including terms, conditions and benefits; consider recommendations for individual pay on the basis of individual appraisals and to consider the Charity’s human resource strategy. The committee comprises the Chair of the Board of Trustees and at least two other Trustees.

The organisation is comprised of Coeliac UK, a registered Charity, and its subsidiary The Coeliac Trading Company Ltd. The principal activity of the trading subsidiary is to raise funds on a commercial basis for the Charity to support its charitable activities. The subsidiary is governed by two directors appointed from the senior management team of the Charity, one Trustee from the Board of the Charity, and chaired by an independent director. In December 2023, the assets and operations of The Coeliac Trading Company Ltd were transferred to Coeliac UK. Following the transfer, The Coeliac Trading Company Ltd became dormant and ceased to trade.

The Board of Trustees

The Board of Trustees lead the Charity in setting its strategic direction and agreeing objectives and plans to deliver the Charity’s aims. The Board monitors and evaluates the progress of the Charity to ensure it achieves those objectives and plans.

Page 5

Annual Report and Financial Statements for the year ended 31 December 2024

Coeliac UK

The expertise within the Board is substantial, wide-ranging and importantly complementary. Trustees include director-level individuals from finance, fundraising, HR, marketing, law and healthcare backgrounds. All Trustees are volunteers committing many hours to the work of the Charity.

The Board’s Committees/Councils

The Board delegates some of its responsibilities to specialist groups to provide particular focus and expertise on key issues and opportunities:

Audit Investment and Risk Committee

This committee ensures the robustness of the Board’s overall financial and risk monitoring. The role of the Committee is to support the Board of Trustees in monitoring the adequacy of the Coeliac UK’s corporate governance and control systems by offering objective advice on issues concerning the risk, control and governance of the organisation and associated assurances provided by external audit and other processes. It ensures the Charity’s financial management meets the standards of good practice accepted by the Charity Commission and Companies House.

People Committee (see Management and staff above)

This committee oversees the Charity’s HR policies ensuring they are legally compliant and fit for purpose.

Executive Action Committee

This committee allows the Board to retain control in crisis situations when the full Board may not be able to be convened. The Committee would only be called upon in emergencies and has not been invoked in recent years.

Health Advisory Council (HAC)

This committee brings expert insight into health issues related to coeliac disease, associated research and advice on related policies and activities. The Council draws upon a wide range of expertise to reflect all aspects of healthcare and includes representation from across all four UK nations.

Food Standards Committee (FSC)

This committee provides the Charity with additional technical expertise and independent appraisal of the standards applied to its licensing and accreditation activities. It also engages with other industry and regulatory bodies to ensure the exchange of ideas and state of the art information.

Research Strategy Board (RSB)

In addition to bringing expert knowledge and experience, the RSB fulfils governance requirements for the review and development of the Charity’s research strategy which underpins the Charity’s Research Fund.

Research Awards Panel (RAP)

This committee manages the awards process for grants under the Research Fund. It provides the Charity with expert insight and fulfils governance requirements for the review, funding and management of the Charity’s research awards in line with the Charity’s Research Strategy. The

Page 6

Annual Report and Financial Statements for the year ended 31 December 2024

Coeliac UK

Panel reports to the Board of Trustees.

Fundraising Committee

This committee brings the Charity expert insight and fulfils the governance requirements for the detailed scrutiny and oversight of the fundraising undertaken for the Charity including for the Research Fund.

Commercial Committee

This committee provides the Charity expert insight to help plan the Commercial Services strategy and deliver its activities.

Board of the Trading Company

In late 2023, the assets and operations of The Coeliac Trading Company Ltd were transferred to Coeliac UK, and the Directors of the subsidiary have decided that the company shall remain dormant for the foreseeable future.

Meeting Protocol

The Boards and committees continued to use a combination of face-to-face meetings, video calls and teleconferences during the year to review plans and activities of the Charity and ensure the cost effectiveness of their operations.

Recruiting and Supporting Trustees

The Board of Trustees regularly undertakes an audit to identify current and emerging skills gaps. Vacant roles are advertised widely both in the Charity’s communications to members and on recruitment websites open to all. The selection process comprises shortlisting based on CVs and supporting statements, followed by an interview panel for shortlisted candidates. Following appointment, new Trustees are provided with induction packs, formal training as required for the role, and sessions spent with key staff.

Our Approach to Fundraising

As a charity registered with the Fundraising Regulator, we strive to achieve the highest standards in all our fundraising activities, referring to all relevant professional and statutory bodies as guidance and regulation develops. Our aim to develop positive long-term relationships with our members, donors and supporters underpins all our actions in this area.

Coeliac UK operates with a small team of in-house staff to lead and develop its fundraising. Fundraising staff are expected to act professionally at all times, follow the Fundraising Regulator’s Code of Conduct and are encouraged to undertake training to develop their knowledge. Fundraising staff receive a salary but are not eligible for a performance bonus.

We also use the services of several carefully selected external companies who provide specialist skills to help us deliver specific activities. These include a telephone agency, as well as a raffle and lottery manager. With each of these companies, we have signed agreements, committing them to adhere to both the letter and spirit of the regulations.

Any complaints that fundraising activity may generate are recorded and investigated by the appropriate line manager to ensure future learning opportunities in fundraising. Coeliac UK is pleased that its fundraising activity generates few complaints annually. In 2024, we received 14 complaints. All complaints were quickly resolved without escalation.

Page 7

Annual Report and Financial Statements for the year ended 31 December 2024

Coeliac UK

Managing Risk

The Trustees are responsible for ensuring appropriate financial and other controls are in place. At Coeliac UK, the role of risk management is delegated to the Audit, Investment and Risk Committee who review the risk quarterly and report back to the full Board.

A risk register is used by the Board and staff to review the main risks and uncertainties, and systems put in place for management and mitigation. The register is regularly updated and monitored by the executive team and Board as work progresses and risks emerge through the year.

The key risks are made up of financial, operational, regulatory, external and strategic risks; and the main residual high risk identified (after mitigating actions) in 2024 was that income raised from all fundraising channels does not meet the budget target for net income.

Page 8

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2024

Report of the Board of Trustees

The Board of Trustees who are the Charity Trustees, and Directors of Coeliac UK (‘the charitable company’/’the Charity’), have pleasure in presenting their report, which incorporates the report of the Directors for the purposes of company law, and the accounts for the year ended 31 December 2024.

Restated financial statements

The financial statements for 2023 have been restated from those previously approved by the Trustees on 3 September 2024. Expenditure has been restated to correctly represent the activity in the year.

Introduction

2024 was another challenging year, as external pressures continued to shape our work. The cost-of-living crisis remains a significant concern for many people with coeliac disease, and reporting on and addressing these challenges has been a key focus of our efforts throughout the year.

A strategic review during the year, confirmed that our direction remains strong, and by refining our vision, mission, values, and key activities, we have renewed our commitment to ensuring that no life is limited by coeliac disease. A long-overdue move to a new office at the start of the year has fostered greater collaboration across the charity, strengthening our impact.

We are immensely grateful to our staff, volunteers, supporters, partners, and donors, whose dedication makes our work possible. With the NHS under increasing strain, Coeliac UK remains a vital source of support for those living with the condition. Time and again, people tell us how much they value our work, and we are determined to reach even more individuals, delivering stronger support and better outcomes for our community.

Alongside our partners in the health and food sectors, we continue to lead efforts to raise awareness, improve understanding, and increase diagnosis rates. Looking to the future, we remain committed to funding research that improves management of coeliac disease, drives the development of new treatments, and, ultimately, finds a cure.

Major Achievements

Page 9

Annual Report and Financial Statements for the year ended 31 December 2024

Coeliac UK

Diagnosis & Equality

“I was diagnosed last year and it came as a total shock, the support knowledge and information I have gained from coeliac UK has been fantastic.” Gillian, Dunfermline

“The support Coeliac UK offered me throughout the diagnosis process was invaluable.” Molly, Loughborough.

“Coeliac UK has been instrumental in driving better understanding, diagnosis and care for people with coeliac disease. Their work has empowered both healthcare professionals and patients, creating a tangible impact on the lives of people.” Nick Trott, Gastro Dietitian, Sheffield Teaching Hospital

We continued our work to increase the number of people diagnosed with coeliac disease and strive for greater equity to the diagnosis pathway.

Our Coeliac Awareness Month (run throughout May 2024) garnered media coverage worth the equivalent of £4.4 million in PR value, including 5 diverse case studies covering a range of symptoms. Aiming to increase knowledge about coeliac disease, our awareness raising work also empowered 43,000 people to begin their diagnosis journey by completing the ‘Is It Coeliac Disease?’ assessment.

Throughout the year, our work enabled 17.5 million organic social media impressions, and we grew our social media community to over 200,000 followers.

Our network of healthcare professional members is crucial in enabling people to access a diagnosis as well as providing ongoing care in both primary and secondary healthcare settings. This network grew in 2024, as we reached out to even more GPs at their annual conference, and consequently a wider group of patients.

Page 10

Coeliac UK Annual Report and Financial Statements for the year ended 31 December 2024

Support

“Thanks to Coeliac UK, I’ve learned to adapt to life without gluten. I rely on the charity to help me stay healthy and feel good.” Ben, Telford

“The support and advice we received from Coeliac UK has given us the confidence to adapt and help educate other people in our daughter’s life.” Anita, Oxford

“It’s so nice being out with a group where I’m not ‘special’ or even a nuisance. It’s so nice not to have to explain myself and be with a bunch of friends.” Russ, South Gloucestershire

We’re here for everyone who needs to live gluten free. In 2024, we continued to work relentlessly for all our community including over 61,000 members.

We were delighted to engage with nearly 20,000 people face to face at community led events, Coeliac UK activities, regional shows, festivals and events across the UK, helping everyone to feel included, supported and less isolated.

Our website proved again that it is a vital resource for everyone, with over 1.3million active visits. Work began on a new website for delivery in 2025 – a major project due to the diverse nature of our work and range of stakeholders.

We also welcomed even more people to join our trained volunteers growing this group by 20%, all of whom helped to deliver over 350 community events, nationwide. We are especially delighted to see that our Teen Virtual Club has supported over 100 teenagers with coeliac disease, enabling them to share their experiences with one another as well as a enjoying a ‘cookalong’ with Becky Excell. Young people of all ages were supported through our printed and online materials, with 348 packs distributed.

Our Helpline services continue to support every aspect of living gluten free, managing over 18,000 enquiries this year, providing a vital lifeline to many people who have nowhere else to turn. Over 250 families were supported through our dietitian-led diet and health workshops, receiving glowing feedback.

The Food Information Service is a constant source of support for our community, shown by an average of over 9,000 web and app visits every month. Featuring information on over 190,000 food products, it is an invaluable service, with the app version adding an extra dimension of a barcode scanner, making shopping gluten free much easier.

Knowledge of our community and their needs was further demonstrated by the use of the Home of Gluten Free Recipes, another key service. The service had an average of over 30,000 visits a month, peaking in December with over 70,000 visits.

Page 11

Coeliac UK Annual Report and Financial Statements for the year ended 31 December 2024

Access

“Coeliac UK has helped me come to terms with the disease and provided information on what is available. The accreditations for restaurants have been particularly useful when out and about.” Geraldine, Winchester

“From the very beginning, Coeliac UK have been an invaluable partner in helping us to truly understand the audience and landscape.” Lauren Harber, Genius

“Coeliac UK’s expertise and dedication have allowed us to make a real difference in the lives of our customers.” Alex Murphy, BFree

As the gluten free diet is the only treatment for coeliac disease, the availability of gluten free alternatives, and people’s ability to access them, are focus areas that continue to drive our efforts.

Working together with food industry partners, through our food safety schemes and pulling on our expertise, we work to ensure that their products are safe, suitable and attractive to our community.

With the Crossed Grain trademark scheme (available to be used throughout the world), manufacturers can easily show to consumers which products are suitable for a gluten free diet. We were delighted to welcome 16 new manufacturing partners to this food safety scheme in the UK during 2024, meaning that around 1,700 food products now carry the CGT in the UK.

Eating out of the home continues to be one of the biggest challenges for people with coeliac disease, as the danger of cross-contamination, where even a small crumb of gluten can reignite the devastating immune reaction that causes damage, is harder to control.

The Gluten Free Accreditation (GFA) scheme for caterers provides a great support to those who work in the catering industry, assisting and supporting them to develop the best processes, checks, menus and service for people who need a gluten free diet. Seventeen new GFA partners came on board in 2024, increasing the number of venues and locations throughout the UK that have confidence in providing gluten free meals to over 3,000, supporting our community wherever they are.

The training programmes linked to these food safety schemes are also vital additions to ensure gluten free food is available. Compared to the previous year, we are pleased to report an 80% increase in the number of people trained in catering gluten free, including chefs, auditors and food technicians across multiple sectors.

Elsewhere, our communications to our members and wider community means we can offer manufacturers the opportunity to promote their products, particularly new additions, to this audience. We would like to acknowledge the support of Warburtons, Panasonic, Coop, Nestle GoFree and Dr Schar for their sponsorship of some of our key activities.

Coeliac UK is uniquely placed to recognise and understand both the needs of people who require a gluten free diet, and the requirements of companies who can provide those products. Additionally, our expertise in the gluten free diet, amassed over half a century, means we have the knowledge and competency to represent our community on the global stage.

Page 12

Annual Report and Financial Statements for the year ended 31 December 2024

Coeliac UK

Our efforts this year at the Codex Alimentarius Commission (the international food standards body established jointly by the Food and Agriculture organization (FAO) and the World Health Organization (WHO) in May 1963 with the objective of protecting consumer’s health and ensuring fair practices in food trade), held in Canada in 2024, has ensured that coeliac disease will not be missed or forgotten from any amendments to changes coming down the line in global food standards that are set by this body. This work is vital to ensure that gluten free food – the only treatment for coeliac disease – remains available and accessible to everyone who needs it.

Advocacy

“It is difficult to imagine what life would be like without Coeliac UK. It is always my ‘keystone’; it’s the organisation in which I have the most trust and one that I compare other sources against and believe the most.” Jim, Staffordshire

“I know from first-hand experience of working with Coeliac UK that the work they do in supporting and standing up for those living with coeliac disease is so important.” Rhun Ap Iorwerth, MS, Chair of the CPG in Wales

Representing the views and needs of our community has always been a key mission for the charity, and this has become even more important. The cost of living difficulties being encountered by so many people, can affect those on a gluten free diet disproportionately as their food costs are markedly higher.

Work started in 2023, was continued in 2024, through the publication of our updated report "The gluten free diet: What does it cost and why does it matter?". Within it, we were able to provide the latest data on the cost of the gluten free diet, drawing on a survey of around 1,000 shoppers. It showed beyond doubt that a weekly shop for a gluten free consumer can be as much as 35% more expensive than a standard gluten-containing food shop. The cost of the cheapest loaf of gluten free bread can be as much as six times more expensive than the cheapest gluten containing loaf, gram for gram.

Building on this and other campaigns, we have been engaging with governments and health leaders throughout the UK, involving meetings and events in the devolved nations, including the Senedd Cymru and our first ever event in Stormont, Northern Ireland.

The results of our efforts in raising the profile with policy makers can be tracked by how many times coeliac disease is being mentioned in parliament throughout the year. We saw that mentions of coeliac disease were 56% up across all parliaments compared with 2022, and up 300% in the Houses of Parliaments in Westminster when compared to the same year.

All this work feeds into our ongoing campaigns to raise awareness of the importance of coeliac disease, its diagnosis and management. We continued to work to safeguard gluten free food on prescription through the NHS in many areas of the UK, and to restore this availability in areas of England that have been withdrawn. Wins have been recorded in Sheffield and parts of Kent as provision was restored, but many other areas remain a challenge.

Constant vigilance has been required to ensure that misleading or inaccurate media stories around coeliac disease and the gluten free diet are challenged and corrected. As previously, across the year, we were able to respond to many stories that misrepresented the real need for a gluten free diet .

Page 13

Coeliac UK Annual Report and Financial Statements for the year ended 31 December 2024

Research

“I’m excited by the possibility that research findings in my lab may eventually lead to a potential treatment for coeliac disease.” Dr Mahima Swarmy, University of Dundee

“I’m not alone in this. The advice and support is there. The research is being done. I feel confident with Coeliac UK in my future.” Ruby, Ayrshire

Research into coeliac disease, the causes, treatments and improved diagnosis techniques, remain a key pillar. Our Journey to a Cure campaign continued to raise funds and awareness into the need for research, with over £100,000 donated by our community.

Funding raised from donations, grants and legacy gifts and carried forward from previous years, meant that we could approve two major awards (one at the University of Dundee and one at the University of Oxford), committing to a total of £370k expenditure over multiple years.

We were also delighted to approve grants for four sponsored dissertations, all receiving up to £5000. Initially it was planned to award only two grants, but all the submissions were of such high quality, that all were given the go ahead.

We were also able to continue to fund four previously awarded projects.

Our commitment to supporting research was further demonstrated as we were able to support 17 external projects, in total worth c£1.7million. This was mainly by providing the public patient involvement activity – a mandatory element in all medical research.

A global perspective on research was provided at the 20th International Celiac Disease Symposium held in Sheffield in September. The prestigious event of the International Society for the Study of Celiac Disease, for which Coeliac UK provides administrative support, was hosted by the Sheffield Teaching Hospital. Around 600 people from across the globe attended 3 days of presentations, events and seminars to promote scientific knowledge, education and quality of care.

Through the generosity of our supporters, Coeliac UK was able to sponsor twelve UK-based dietitians to attend the ICDS as part of our commitment to support the continued professional development of healthcare professionals who are so crucial to the provision of high-quality care for patients with coeliac disease.

“The chance to attend such a prestigious international conference was invaluable. The insights I gained are already influencing our practice, leading to improved care for the patients we serve.” Justice Kofi Amegashie, gastroenterology specialist dietitian, Great Western Hospitals, Swindon

Page 14

Annual Report and Financial Statements for the year ended 31 December 2024

Coeliac UK

Plans for 2025

In 2025 and beyond, the Charity will focus on delivering objectives that are aligned with our new strategic pillars which support our mission of no life limited by coeliac disease. In addition to “business as usual” activity, we plan to:-

Diagnosis of coeliac disease

A key focus in 2025 will be increasing diagnosis of coeliac disease through awareness activities, underpinned by our flagship Awareness Month campaign in May. This campaign will target individuals with undiagnosed symptoms, those requiring ongoing support, healthcare professionals, and commercial partners. Community engagement will expand through social media, online events, and in-person initiatives, targeting a wider demographic.

We will continue our core work around improving diagnosis, contributing to the development of updated guidelines for coeliac disease and associated conditions such as Type 1 diabetes, faltering growth, and autoimmune thyroid disease. We will participate in healthcare professional (HCP) education days and initiate the new Clinical Champions programme to promote best practices in diagnosis, treatment, and long-term support. Additionally, we aim to raise awareness among healthcare professionals beyond GPs, gastroenterology and dietetics, including dentists, hepatologists, and mental health practitioners.

Support for people with coeliac disease

We will undertake a comprehensive review of our membership model and package options to ensure they effectively showcase the value of our expertise, support services, and resources. This process will inform a refined membership proposition aligning with our strategic goals. Our efforts will focus on four key themes:

A key priority in 2025 will be expanding support for community events. This will include increasing the number of volunteer-led local activities across the UK, enhancing our presence at external food festivals and county shows, and organising national Gluten Free Food Market(s) to bring together consumers, businesses, and experts in one space.

We will also continue to develop dedicated support resources for children and young people, providing opportunities for peer connection and ensuring age-appropriate tools and information are readily available.

Access to gluten free food

As part of our commitment to delivering value, we will continue our validation work across all services, ensuring:

Page 15

Annual Report and Financial Statements for the year ended 31 December 2024

Coeliac UK

Additionally, we will continue to showcase our dietetic and health professional expertise by delivering dietitian-led workshops, support videos, and new webinars throughout 2025.

We will focus on enhancing access to safe gluten free food by promoting our food safety schemes, the Crossed Grain Trademark (CGT) and Gluten Free Accreditation (GFA).

The GFA scheme will continue to target hospitality, healthcare, education, and retail sectors, with a structured rollout plan for new accreditations. In 2025, we will implement an updated GFA Standard, ensuring a smooth transition for existing and new partners.

Our digital transformation efforts will enhance the availability of information for potential commercial customers, with a dedicated microsite for food businesses launching in 2025.

Research

Our research program will remain a priority, with continued funding in line with our research priorities, such as studies that may identify key targets in coeliac disease that could lead to new treatment opportunities beyond the gluten free diet. We will relaunch our Research Conference as an in-person event, providing CPD and networking opportunities for healthcare professionals. Additionally, we will conduct a study on the epidemiology and health economics of coeliac disease to support our advocacy efforts.

Advocacy

Advocacy efforts in 2025 will build upon previous work on the cost of gluten free foods, access to safe gluten free options in public sector settings, improving diagnosis and management of coeliac disease. We will continue public affairs work to engage policymakers across all four nations, host parliamentary events, and pursue meetings with Health Ministers, commencing in Q1 2025 with a hand-in to 10 Downing Street of our petition to retain/renew gluten free prescribing.

We will ensure that coeliac disease and the gluten free diet remain a focus at both national and international levels e.g. at the Codex Alimentarius, the most important international body in the field of food standards. We will support ongoing research on gluten thresholds and reference doses to provide further evidence to underpin key food standards that will improve conditions for our community.

People and Culture

In 2025 and beyond, we will continue investing in training, development, and recruitment to retain and attract top talent. A key activity is the development of the Coeliac UK Employee Value Proposition, which will include a comprehensive review of employee benefits. We will continue to promote staff wellbeing, gauging through regular mental health surveys and improving through agreed workplace improvements.

We will strengthen the team by recruiting 5 new key roles across the Charity that will be vital in the achievement of our strategic goals

Page 16

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2024

Technology

We will launch our new website in the Summer of 2025. This will expand our reach to new audiences, whilst enhancing the online experience for existing supporters. Elsewhere, we will continue to invest and develop our technology solutions, and explore systems integrations to enhance productivity and minimise error.

Fundraising and Communications

We will continue to develop long-term relationships with supporters and broaden our portfolio of voluntary income streams. Our approach will ensure that supporting Coeliac UK is a positive and fulfilling experience by improving how we engage, steward, and thank donors.

A particular focus is to increase our sustainable income through regular donors. We plan to grow the number of people giving to Coeliac UK on a regular basis, whether through donations alongside membership payments, direct debits, payroll giving, or recurring card payments. As the membership offering evolves, we will explore new opportunities for regular donations, topups, and other innovative giving methods.

Our gambling products, including the Gluten Free Weekly Lottery and regular raffles, remain key revenue sources. We will focus on expanding the lottery to non-membership audiences through digital and face-to-face engagement. Raffles, a well-established fundraising method, will continue to be optimised for cost efficiency and player growth.

Challenge events offer both financial support and an opportunity to engage new audiences. In 2025, we will gradually increase the number of places available in key events while encouraging individuals to enter on their own initiative. Enhanced supporter stewardship will maximise funds raised and provide compelling case studies for broader charity use.

To sustain core activities and increase our research funding, we will continue our efforts to grow individual giving. This will include at least one dedicated appeal for research funding utilising a peer-reviewed project aligned with the Charity’s vision. Donation requests will feature prominently on the new website and in supporter newsletters and other communications.

Page 17

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2024

Financial Review

Overview

The Charity has three main sources of funding: membership fees, commercial services our restaurant accreditation scheme and licensing of the Crossed Grain Trademark), and fundraising from donations (including from gifts in wills). We also raise money through our raffles and lottery, and through grant income.

These funds enable us to provide services and information to support those diagnosed or caring for someone with coeliac disease in living a gluten free life and also in providing guidance and advice to those seeking diagnosis. We are actively engaged in campaigning with the health and food sectors to educate and raise awareness to increase understanding of the condition and the treatment required. In the longer term, these income streams enable the Charity to fund research to improve management of the condition, the development of treatments and ultimately a cure.

The Charity had a net deficit of £436k for 2024, an increase of £184k on 2023 (£252k). Whilst we were able to grow income, our expenditure increased by more as we continued our investment in the Charity to provide an exceptional service and support to our beneficiaries and prepare for our next strategic period.

The Charity’s total income in 2024 was £4,478k, an increase of £227k from £4,251k income in 2023. Income from trading and charitable activities totaled £2,631k in 2024, up over 7% on the £2,448k generated in 2023.

The income from donations and legacies was £1,778k, £40k (2%) higher than the £1,738k received in 2023. We continue to benefit from the long-term investment in developing Gifts in wills, with a Legacies income of £760k (down from an incredible £969k in 2023). The addition of a third Raffle in late 2024 contributed to the overall growth in this area, along with continued growth in our Lottery, corporate and other donations.

Income from Memberships was down slightly to £1,140k. Whilst we achieved are planned levels of renewals and new member acquisition, our re-activation of lapsed memberships was disappointing and alongside the continued migration from full to digital memberships contributed to the lower than planned income.

Overall, we achieved an investment income of £69k on our investments up 5% on 2023 (£65k), comprising £27k in bank interest and a further £42k in dividends.

Expenditure in 2024 increased to £4,951k, some £424k more than the £4,527k spend in 2023. This increase was largely driven by an increase in our expenditure on charitable activities (+£282k), especially Raising Awareness and supporting our Members. We also spent a further £166k raising funds, driven by our investment in growing donations and Gifts in Wills. Our total expenditure on Research fell from the high level of £688k in 2023, equivalent to over 16% of income to a still commendable 10% (£449k) in 2024.

Our focus in 2025 will be on continuing to develop the broader portfolio of sustainable income streams, and careful management of expenditure, to ensure that we achieve a good return on investment for our members, donors and supporters and deliver improving outcomes for our beneficiaries in line with our strategic objectives.

Page 18

Annual Report and Financial Statements for the year ended 31 December 2024

Coeliac UK

Investing in research

Having committed £435k in research awards in 2023, we made further awards of £360k in 2024 (this was offset by the withdrawal of an unspent award of £91k) to both better understand coeliac disease (£103k), and also to develop potential treatments (£249k).

Investment policy and Performance

The objective of the Charity’s Investment Policy is to achieve a return on the charity’s investment assets, including cash and other liquid or short-term investment assets, to further the charity’s aims and meet the charity’s future funding requirements whilst having regard to the risk parameters agreed by the Board of Trustees. The portfolio should provide a return (after any fees) that at a minimum matches or betters inflation while preserving the capital value. The Charity should also retain sufficient liquid resources to enable it to effectively meet its short-term obligations and provide adequate cover to meet any unplanned or unbudgeted expenditure. Furthermore, to ensure that environmental, social and governance (ESG) impact of the investment funds are considered, the charity’s assets are not invested in shares or any other financial instrument of a company whose objectives are contradictory to those of Coeliac UK.

Funds that are unlikely to be required over the long-term (5 years or more) are invested in long-term capital funds, whilst funds required in the short-term are invested in low risk but high liquidity interest-bearing funds.

In 2024, short-term cash deposits were invested in the overnight money market (HSBC). Bank interest received from our cash deposits in 2024 was £26.7k.

In addition, at 31 December 2024 the Charity had £1,020k invested with fund manager Cazenove Capital, in their “Charity Sustainable Multi Asset Fund”, which the Trustees are satisfied meets its objectives as described in the Investment Policy. In 2024, this fund paid dividends of £41.8k and achieved an unrealized gain of £37.4k.

The Charity regularly reviews its cash and investment position and will consider further investment in 2025.

Page 19

Annual Report and Financial Statements for the year ended 31 December 2024

Coeliac UK

Reserves policy

The Board recognises the need to hold charitable funds as free reserves to safeguard the continuity of provision of basic services, to fund periods of expenditure in excess of revenue and to fund unexpected expenditure.

As part of the 2024 year-end review process, the Board of Trustees used Charity Commission guidelines to conduct an annual review of the reserves policy.

The Board agreed to maintain the policy that sufficient reserves will be held to ensure the Charity can continue to operate and meet its charitable commitments, should there be a time when income has been adversely impacted. This is to allow time to assess and implement the future options for the Charity. Excess reserves will be designated for a specific activity when an appropriate and timely use of the funds has been identified and agreed by the Board. In the event there are no extra reserves, the Board may utilise the operational reserves to meet any of the above needs should they arise, subject to a cost benefit analysis.

The target level of reserves as at 31st December 2024 has been calculated at £901k, being the mid-point within the range £707k to £1,094k. The Reserves target is calculated by assuming an average reduction in 12-months forecast income of 25% offset by a forecast reduction in discretionary costs over the same period, equal to a reduction in total costs of approximately 7.4%. We ended the year with free reserves of £1,346k, some £445k above the target. We will continue to invest our surplus reserves in our charitable activities over the next strategic period, helping us deliver our mission of no life limited by coeliac disease.

The Board also wish to maintain a level of liquid reserves that ensures the Charity can meet its obligations as they fall due. The level of liquid reserves required and liquid reserves available is reviewed regularly throughout the year. As at 31st December 2024 the Charity had £1,820k in liquid assets, comprising £800k cash and £1,020k in other liquid investments.

Of our restricted reserves of £245k, we had £233k held for our Research Fund. From time to time, we raise funds solely for research to build a sufficient sum to launch a research call for grant applications.

Going Concern

Management and the Trustees regularly review detailed forecasts of income, expenditure and cash flows. The assumptions underlying the budget and forecasts are challenged, varied and tested to establish the likelihood of a range of possible outcomes including reasonable cash flow sensitivities. The forecast performance is monitored against actual outcomes each month and variances analysed and discussed at Management and Board level.

The Trustees have reviewed cash flow forecasts for the period to 31 December 2026. The cash flow forecasts indicate that the Charity will be able to meet its liabilities as they fall due for the period until at least 31 December 2026. In the event that income does not achieve projected levels, management is able to adjust discretionary expenditure to relieve any short-term cash pressures which might arise.

The Trustees are therefore satisfied that the financial statements should be prepared on the going concern basis.

Page 20

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2024

Responsibilities of the Board of Trustees

The Board of Trustees (who are also directors of Coeliac UK for the purposes of company law) is responsible for preparing the Report of Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Board of Trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for the year. In preparing these financial statements, the Trustees are required to:

The Board of Trustees is responsible for keeping adequate accounting records which are sufficient to show and explain the charitable company’s transactions and which disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 and the Charitable Company’s constitution. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

So far as the Board of Trustees are aware:

The Board of Trustees is responsible for the maintenance and integrity of the corporate and financial information included on the charitable company’s website. Legislation in the United Kingdom governing the preparation and dissemination of the financial statements may differ from legislation in other jurisdictions.

This report has been prepared in accordance with the Special Provisions of Part 15 of the Companies Act 2006 relating to Small Companies.

This report was approved and authorised for issue by the Board of Trustees on 24 April 2025 and signed on their behalf by:

Registered Company Number: 03068044

Chris Dilloway Chair

Page 21

Annual Report and Financial Statements for the year ended 31 December 2024

Coeliac UK

Independent auditors' report to the members and trustees of Coeliac UK

Opinion

We have audited the financial statements of Coeliac UK (the parent charitable company') and its subsidiaries (the 'group') for the year ended 31 December 2024 which comprise the group statement of financial activities, group and parent charity balance sheet and group statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRCS Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of of assurance conclusion thereon.

Page 22

Annual Report and Financial Statements for the year ended 31 December 2024

Coeliac UK

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information we are required to report that fact.

We have nothing to report in this regard.

Other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and the parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Board of Trustees.

We have nothing to report in respect of the following matters where the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

Responsibilities of Trustees

As explained more fully in the Statement of Responsibilities of the Board of Trustees set out on page 15, the Trustees (who are also the directors of the parent charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of the financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the parent charitable company or to cease operations, or have no realistic alternative but to do so.

Page 23

Coeliac UK Annual Report and Financial Statements for the year ended 31 December 2024

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditors under the Companies Act 2006 and under the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with regulations made under those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted In accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud.

Page 24

Coeliac UK Annual Report and Financial Statements for the year ended 31 December 2024

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and Implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud Identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the charitable company.

Our approach was as follows:

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of noncompliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may Involve deliberate concealment by, for example, forgery or Intentional misrepresentations, or through collusion.

Use of our report

This report is made solely to the charitable company's members, as a body, In accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company's trustees as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company, the charitable company's members and trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Page 25

Annual Report and Financial Statements for the year ended 31 December 2024

Coeliac UK

Date: 23 May 2025 James Saunders (Senior Statutory Auditor) 9 Appold Street Moore Kingston Smith LLP London Statutory Auditors EC2A 2AP

Moore Kingston Smith LLP is eligible to act as auditor in terms of Section 1212 of the Companies Act 2006.

Page 26

Annual Report and Financial Statements for the year ended 31 December 2024

Coeliac UK

Consolidated statement of financial activities (including consolidated income and expenditure account)

----- Start of picture text -----
Notes Unrestricted Restricted 2024 2023 Restated
funds funds Total Total
£ £ £ £
Income
Donations and legacies 2 1,519,089 259,290 1,778,379 1,737,619
Income from charitable activities 2 2,075,875 40,000 2,115,875 1,981,672
Income from trading activities 2 515,224 0 515,224 466,739
Investment income 2 68,522 0 68,522 64,999
Total income 4,178,710 299,290 4,478,000 4,251,029
Expenditure
Expenditure on raising funds
Donations and legacies 536,138 0 536,138 370,365
Trading activities 400,311 0 400,311 423,947
Expenditure on charitable activities 3 3,726,470 288,465 4,014,935 3,732,529
Total expenditure 4,662,919 288,465 4,951,384 4,526,841
Net gains on investments 11 37,389 - 37,389 23,947
Net income / (expenditure) for the year 7 (446,820) 10,825 (435,995) (251,865)
Balances brought forward 2,117,443 234,265 2,351,708 2,603,573
Total funds carried forward 1,670,623 245,090 1,915,713 2,351,708
----- End of picture text -----

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities. The notes on pages 30 to 45 form part of these financial statements.

Page 27

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2024

Consolidated statement of cash flows
Cash flows from operating activities:
Net cash used by operating activities
Cash flows from investing activities:
Dividends from investments
Bank interest
Purchase of fixed assets
Purchase of investments
Net cash used in investing activities
Decrease in cash in the year
Cash at the beginning of the year
Total Cash at the end of the year		 2024
£
(423,960)
41,836
26,686
(114,559)
-
(46,037)
(469,997)
1,269,542
799,545		 2023
Restated
£
(270,481)
24,454
40,545
(205,816)
(634,783)
(775,600)
(1,046,081)
2,315,623
1,269,542

Page 28

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2024

Consolidated balance sheet

GROUP CHARITY CHARITY
Notes 2024 2023 2024 2023
Restated Restated
£ £ £ £
FIXED ASSETS
Tangible assets 10 157,966 156,996 157,966 156,996
Intangible Assets 10 121,173 115,172 121,173 115,172
Investment & deposits 11 1,019,969 982,582 1,019,969 982,582
1,299,108 1,254,750 1,299,108 1,254,750
CURRENT ASSETS
Sundry Debtors 12 1,699,957 1,604,688 1,699,957 1,716,594
Cash at Bank 799,545 1,269,542 799,485 1,157,636
2,499,502 2,874,230 2,499,442 2,874,230
CURRENT LIABILITIES
Creditors - falling due within one year 13 (1,873,897) (1,777,272) (1,873,896) (1,777,272)
NET CURRENT ASSETS 625,605 1,096,958 625,546 1,096,958
Total assets plus current liabilities 1,924,713 2,351,708 1,924,654 2,351,708
Provisions for liabilities and charges 14 (9,000) - (9,000) -
NET ASSETS 1,915,713 2,351,708 1,915,654 2,351,708
The funds of the charity
Unrestricted funds
Designated 15 45,640 93,223 45,640 93,223
General 1,624,983 2,024,220 1,624,924 2,024,220
1,670,623 2,117,443 1,670,564 2,117,443
Restricted funds 16 245,090 234,265 245,090 234,265
Total charity funds 1,915,713 2,351,708 1,915,654 2,351,708

The Trustees have prepared group accounts in accordance with section 398 of the Companies Act 2006 and section 138 of the Charities Act 2011. These financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

As permitted by s408 Companies Act 2006, the company has not presented its own Statement of Financial Activity and related notes. The Company's loss for the year was £435,994 (2023 restated: £242,301).

Approved by the Board of Trustees and authorised for issue on__these financial statements are signed on their 24 April 2025 behalf by:

Chris Dilloway - Chair

Company number: 03068044

The notes on pages 30 to 45 form part of these financial statements.

Page 29

Annual Report and Financial Statements for the year ended 31 December 2024

Coeliac UK

Notes to the financial statements

1 ACCOUNTING POLICIES

1.1 Basis of preparation

The financial statements have been prepared in accordance with the Financial Reporting Standard applicable in the UK (FRS102) and (Charities SORP (FRS 102) and the Companies Act 2006.

Coeliac UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note.

There are no material uncertainties about the charity's ability to continue as a going concern. The charity's planned activities, together with its financial position; management of risk and approaches to investments, cashflow and reserves are described in the Report of the Board of Trustees. As a consequence, the Trustees believe that the charity is well placed to manage its risks successfully despite the current uncertain economic outlook. The Trustees have a reasonable expectation that the charity and the group have adequate resources to continue in operational existence for the foreseeable future. Accordingly, they continue to adopt the going concern basis in preparing the annual report and accounts.

1.2 Local groups and accounting policy

The local groups record their income and expenditure on a receipt basis. At the end of the financial year, each group submits a return of its income and expenditure which is included in the Statement of Financial Activities and the Balance Sheet.

1.3 Income

Income from web advertising, sponsorship and licensing, and accreditation is deferred on a proportionate basis over the life of the contract. All other income is recognised when the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Donations and legacies includes donations and gifts, legacies, and all other income that is in substance a gift made on a voluntary basis. It also includes grants of a general nature provided by government and charitable foundations which are not conditional on delivery of certain levels or volumes of a service The donation may be made towards the general aims of Coeliac UK (unrestricted), or towards a specific service or aim (restricted). Donations are recognised on receipt of the donation, or if earlier, at the point where there is a written obligation for a donor to pay a specified donation. Legacies are recognised at the point entitlement is established, receipt is considered probable and the estate value can be estimated reliably.

1.4 Cost allocation

Shared costs have been allocated on the following basis:

Description Method of apportionment Depreciation Head count Information technology Head count Support staff costs Head count Office costs Head count

1.5 Grants

Grants payable are payments made to third parties in furtherance of the charitable objectives.

Grants which are free from specific conditions are recognised in full as soon as there is a legal or constructive obligation committing the charity.

Multiyear grants are conditional on an annual review of progress which will determine if future funding is provided. Due to this condition only one year's funding commitment is recognised.

Page 30

Annual Report and Financial Statements for the year ended 31 December 2024

Coeliac UK

Notes to the financial statements (continued)
1.6 Restricted funds
Restricted funds are to be used for specific purposes as specified by the donor. Expenditure which meets
these criteria is charged to the fund.
1.6 Restricted funds
Restricted funds are to be used for specific purposes as specified by the donor. Expenditure which meets
these criteria is charged to the fund.
1.7 Depreciation of fixed assets
Provision is made for depreciation on all assets at rates calculated to write off the cost, less any
estimated residual value of each asset over its expected useful life, as follows:
Furniture and fittings
20% p.a. straight line
Computer equipment
33.33% p.a. straight line
Intangible assets
33.33% p.a. straight line
1.8 Investment & Deposits
Investments held as current assets are at the realisable value at the balance sheet date.
1.9 Leasing
Rental payable under operating leases are charged against income on a straight-line basis over the lease
term.
1.10 Expenditure
Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third
party, it is probable that settlement will be required and the amount of obligation can be measured
reliably. Costs are analysed between expenditure on charitable activities and costs of raising funds of the
charity. Any direct costs are allocated between restricted and unrestricted funds as incurred.
1.11 Designated funds
Designated funds are unrestricted funds earmarked by the board of Trustees for particular purposes.
1.12 Pension
The charitable company operates a group personal money purchase pension scheme. The pension cost
charged in the financial statements represents contributions payable by the charity during the financial
year. The Charity previously operated a defined benefit pension scheme which is now closed to new
members. The scheme is also closed to future accrual. The Charity continues to make contributions as
set out in note 21.
1.13 Basis of consolidation
The group accounts consolidate the accounts of Coeliac UK and its subsidiary undertaking on a line by
line basis. The accounts are made up to 31 December 2024. No separate statement of financial activities
or income and expenditure has been presented for the charity alone as permitted by section 408 of the
Companies Act 2006.
1.14 Financial instruments
The charity only has financial assets and liabilities of a kind that qualify as basic financial instruments.
Basic financial instruments are initially recognised at transaction value and subsequently measured at
their settlement value.
1.15 Critical accounting judgements and key sources of estimation uncertainty
In the application of the charity's accounting policies, the trustees are required to make judgements,
estimates and assumptions about the carrying amount of assets and liabilities that are not readily
apparent from other sources. The estimates and associated assumptions are based on historical
experience and other factors that are considered to be relevant. Actual results may differ from these
ti
t
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting
estimates are recognised in the period in which the estimate is revised where the revision affects only
that period, or in the period of the revision and future periods where the revision affects both current
and future periods.
1.16 Intangible Asset Policy
Intangible assets are assets that lack physical substance but have value. Intangible assets are
recognised at cost, which includes the purchase price and any directly attributable costs of preparing the
asset for its intended use. Intangible assets are amortised over their useful life, capped at three years.
1.17 Cash Policy
Cash comprises cash on hand and demand deposits.
Cash equivalents are short-term, highly liquid investments that are readily convertible to known
amounts of cash and which are subject to an insignificant risk of changes in value.

Page 31

Annual Report and Financial Statements for the year ended 31 December 2024

Coeliac UK

Notes to the financial statements continued

2a INCOME
Income from donations and legacies
Donations and gifts
Legacies
Income from charitable activities
Membership
Raising Awareness
Groups
Income from trading activities
Raffle and lottery
Other commercial activities
Investment Income
Investments - dividends
Bank interest		 Unrestricted Restricted
£
239,990
19,300
259,290
-
40,000
-
40,000
-
-
-
-
-
-
299,290		 2024
Total
£
1,018,484
759,895
1,778,379
1,140,438
971,199
4,238
2,115,875
515,224
-
515,224
41,836
26,686
68,522
4,478,000		 2023
Restated
Total
768,396
969,223
778,494
740,595
1,519,089
1,140,438
931,199
4,238		 1,737,619
1,129,754
847,756
4,162
2,075,875
515,224
-		 1,981,672
443,732
23,007
515,224
41,836
26,686		 466,739
24,454
40,546
68,522 65,000
4,178,710 4,251,030

Page 32

Annual Report and Financial Statements for the year ended 31 December 2024

Coeliac UK

Notes to the financial statements continued
2b INCOME
Unrestricted
Income from donations and legacies
Donations and gifts
647,668
Legacies
964,223
1,611,891
Income from charitable activities
Membership
1,129,754
Raising Awareness
812,281
Research
0
Groups
4,162
1,946,197
Income from trading activities
Raffle and lottery
443,732
Other commercial activities
23,007
466,739
Investment Income
Investments - dividends
24,454
Bank interest
40,546
65,000
4,089,827		 Notes to the financial statements continued
2b INCOME
Unrestricted
Income from donations and legacies
Donations and gifts
647,668
Legacies
964,223
1,611,891
Income from charitable activities
Membership
1,129,754
Raising Awareness
812,281
Research
0
Groups
4,162
1,946,197
Income from trading activities
Raffle and lottery
443,732
Other commercial activities
23,007
466,739
Investment Income
Investments - dividends
24,454
Bank interest
40,546
65,000
4,089,827		 Restricted
£
120,728
5,000
125,728
-
35,475
-
-
35,475
-
-
-
-
-
-
161,203		 2023 Restated
Total
£
768,396
969,223
1,611,891
1,129,754
812,281
0
4,162		 1,737,619
1,129,754
847,756
-
4,162
1,946,197
443,732
23,007		 1,981,672
443,732
23,007
466,739
24,454
40,546		 466,739
24,454
40,546
65,000 65,000
4,089,827 4,251,030

Page 33

Annual Report and Financial Statements for the year ended 31 December 2024

Coeliac UK

Notes to the financial statements (continued)

3a Expenditure
Unrestricted
£
Charitable activities
Membership
1,586,258
Raising Awareness
1,729,133
Research
216,049
Groups
195,030
3,726,470
Breakdown of costs of charitable activities
Direct costs
Grants made
(notes 6)
Membership
1,106,751
-
Raising Awareness
1,134,096
-
Research
106,923
268,728
Groups
116,243
-
2,464,013
268,728
Research cost breakdown
Direct costs
Direct Research costs
106,923
Support costs
-
106,923		 Unrestricted
£
1,586,258
1,729,133
216,049
195,030		 Restricted
£
173
55,241
233,051
-
288,465
Support costs
(note 4, 5)
479,681
650,278
73,448
78,787
1,282,194
Grants made
268,728
73,448
342,176		 2024
Total
£
1,586,431
1,784,374
449,100
195,030
4,014,935
2024
Total
1,586,432
1,784,374
449,099
195,030
4,014,935
2024
375,651
73,448
449,099		 2023 Restated
Total
£
1,307,322
1,599,013
688,157
138,036
3,732,528
2023
Total
1,307,322
1,599,013
688,157
138,036
268,728
Direct costs
106,923
-		 3,732,528
2023
607,227
80,930
106,923 688,157

All support costs are allocated on a headcount basis.

Page 34

Annual Report and Financial Statements for the year ended 31 December 2024

Coeliac UK

Notes to the financial statements (continued)

3b
Charitable activities
Membership
Raising Awareness
Research
Groups
Breakdown of costs of charitable activities
Direct costs
Membership
1,004,387
Raising Awareness
1,261,025
Research
172,228
Groups
95,547
2,533,186
Research cost breakdown
Direct Research costs
Support costs
Prior Year Expenditure		 Unrestricted
£
1,307,322
1,476,870
248,928
138,036		 Restricted
£
-
122,143
439,230
-
561,373
Support costs
(note 4, 5)
302,935
337,988
80,930
42,489
764,342
Grants made
434,999
64,375
499,374		 2023 Restated
Total
£
1,307,322
1,599,013
688,157
138,036
3,171,155
Grants made
(notes 6)
-
-
434,999
-		 3,732,528
2023
Total
1,307,322
1,599,013
688,157
138,036
434,999
Direct costs
172,229
16,555		 3,732,528
2023
607,228
80,930
188,784 688,157

All support costs are allocated on a headcount basis.

Page 35

Annual Report and Financial Statements for the year ended 31 December 2024

Coeliac UK

Notes to the financial statements (continued)

4 Total support cost breakdown by activity
Staff costs
Other costs
£
£
Cost of raising funds (note 5)
Donations and legacies
77,646
81,896
Trading activities
32,708
34,497
Charitable activities (note 3)
626,116
658,178
736,470
774,571
Staff costs
Other costs
£
£
Cost of raising funds (note 5)
Donations and legacies
22,185
61,827
Trading activities
16,964
47,274
Charitable activities (note 3)
201,843
562,499
240,992
671,600
5
Support cost apportionment
Support
staff
Depreciation
Governance
HR costs
IT costs
£
£
£
£
£
Expenditure on raising funds
Donations and legacies
77,646
11,375
4,741
7,602
19,760
Trading activities
32,708
4,792
1,997
3,202
8,324
Charitable activities
Membership
233,451
34,200
14,254
22,858
59,410
Raising awareness
316,477
46,365
19,323
30,986
80,539
Research
35,745
5,237
2,182
3,500
9,097
Groups
40,443
5,618
2,341
3,754
9,758
736,470
107,587
44,838
71,902
186,888
Support
staff
Depreciation
Governance
HR costs
IT costs
£
£
£
£
£
Expenditure on raising funds
Donations and legacies
22,185
5,329
2,655
5,905
19,192
Trading activities
16,964
4,075
2,030
4,515
14,674
Charitable activities
Membership
79,998
19,216
9,571
21,292
69,203
Raising awareness
89,254
21,440
10,680
23,755
77,212
Research
21,371
5,134
2,557
5,688
18,488
Groups
11,220
2,695
1,343
2,986
9,706
240,992
57,889
28,836
64,141
208,475		 4 Total support cost breakdown by activity
Staff costs
Other costs
£
£
Cost of raising funds (note 5)
Donations and legacies
77,646
81,896
Trading activities
32,708
34,497
Charitable activities (note 3)
626,116
658,178
736,470
774,571
Staff costs
Other costs
£
£
Cost of raising funds (note 5)
Donations and legacies
22,185
61,827
Trading activities
16,964
47,274
Charitable activities (note 3)
201,843
562,499
240,992
671,600
5
Support cost apportionment
Support
staff
Depreciation
Governance
HR costs
IT costs
£
£
£
£
£
Expenditure on raising funds
Donations and legacies
77,646
11,375
4,741
7,602
19,760
Trading activities
32,708
4,792
1,997
3,202
8,324
Charitable activities
Membership
233,451
34,200
14,254
22,858
59,410
Raising awareness
316,477
46,365
19,323
30,986
80,539
Research
35,745
5,237
2,182
3,500
9,097
Groups
40,443
5,618
2,341
3,754
9,758
736,470
107,587
44,838
71,902
186,888
Support
staff
Depreciation
Governance
HR costs
IT costs
£
£
£
£
£
Expenditure on raising funds
Donations and legacies
22,185
5,329
2,655
5,905
19,192
Trading activities
16,964
4,075
2,030
4,515
14,674
Charitable activities
Membership
79,998
19,216
9,571
21,292
69,203
Raising awareness
89,254
21,440
10,680
23,755
77,212
Research
21,371
5,134
2,557
5,688
18,488
Groups
11,220
2,695
1,343
2,986
9,706
240,992
57,889
28,836
64,141
208,475		 Other costs
£
81,896
34,497
658,178		 Other costs
£
81,896
34,497
658,178		 2024
Total
£
159,542
67,205
1,284,294
1,511,041
2023 Restated
Total
£
84,012
64,238
764,342
912,592
Office
costs
2024 Total
£
£
38,418
159,542
16,183
67,205
115,509
479,682
156,588
650,278
17,686
73,448
18,972
80,886
363,356
1,511,041
Office
costs
2023
Restated
Total
£
£
28,746
84,012
21,980
64,238
103,654
302,935
115,649
337,988
27,692
80,930
14,538
42,489
312,259
912,592		 2024
Total
£
159,542
67,205
1,284,294		 2024
Total
£
159,542
67,205
1,284,294
736,470
Staff costs
£
22,185
16,964
201,843		 774,571
Other costs
£
61,827
47,274
562,499		 1,511,041
2023 Restated
Total
£
84,012
64,238
764,342
671,600
IT costs
£
19,760
8,324
59,410
80,539
9,097
9,758
186,888
IT costs
£
19,192
14,674
69,203
77,212
18,488
9,706
208,475		 912,592
2024 Total
£
159,542
67,205
479,682
650,278
73,448
80,886
1,511,041
2023
Restated
Total
£
84,012
64,238
302,935
337,988
80,930
42,489
912,592
363,356
Office
costs
£
28,746
21,980
103,654
115,649
27,692
14,538
312,259

Page 36

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2024

6 Grants payable
Basic Science Grant PK01-22
Ataxia Project
Children and Young Adults Grant
Dissertations Awarded
Innovate Grant Withdrawn
Rogue cell research to better understand coeliac
disease MF0323
Enzyme inhibitors as a potential treatment for
coeliac disease MS0223		 2024
2023
Restated
£
£
103,180
-
249,201
-
-
248,725
-
157,158
-
29,116
7,880
-
(91,533)
-
268,728
434,999
Grants to institutions		 2024
2023
Restated
£
£
103,180
-
249,201
-
-
248,725
-
157,158
-
29,116
7,880
-
(91,533)
-
268,728
434,999
Grants to institutions
434,999

In accordance with the accounting policy outlined in note 1.5, only the first year of funding commitment is recognised on the accounts for multiyear grants which are conditional on an annual review of progress which determines if future funding is provided.

7 Net incoming (outgoing) resources for the year

This is stated after charging

Depreciation
Operating lease rentals
Trustees liability insurance
Audit services
Non - audit services provided by the auditors
General advice
Tax compliance		 2024
£
107,588
50,681
1,100
13,920
-
2,320
175,609		 2023
Restated
£
66,866
72,412
1,100
15,834
2,085
895
159,192

Travel costs amounting to £2,310 (2023 - £1,316) were reimbursed to Eleven (2023 - 4) members of the Board of Trustees.

Page 37

Annual Report and Financial Statements for the year ended 31 December 2024

Coeliac UK

Notes to the financial statements (continued)

8
Staff costs and numbers
2024
£
Salaries and wages
2,256,588
Social security costs
238,788
Pension costs
120,102
2,615,478
2024
Number
£110,000 - £120,000
1
£100,000 - £110,000
-
£80,000 - £90,000
-
£70,000 - £80,000
3
£60,000 - £70,000
3
The number of employees whose salary amounted to over £60,000 during:		 2023
£
1,860,552
192,822
98,961
2,152,335
2023
Number
-
1
-
-
4

The key management personnel of the group (and charity) comprise the Trustees, the chief executive and senior management team. The total employee benefits ( Salary, Employers National insurance and Employers pension) of the key management personnel of the group were £707,127 (2023: £524,992). None of the Trustees have been paid any remuneration or received any benefits for performing their role as Trustee of the charity.

The average monthly number of employees during the year, calculated on the basis of average headcount was as follows:

Advice and information
Administration and support		 2024
Number
49
10
59		 2023
Number
43
9
52

9 Taxation

The charitable company's activities are exempt from corporation tax in its charitable activities under Sections 466 to 493 of the Corporation Tax Act 2010.

10 Fixed assets - Group and charity

Cost
At 1 January 2024
Additions
Disposals
At 31 December 2024
Depreciation
At 1 January 2024
Charge for the year
Disposals
At 31 December 2024
Net book values
At 31 December 2024
At 31 December 2023		 Intangible
Assets
£
179,100
67,750
-
246,850
63,928
61,749
125,677
121,173
115,172		 Furniture &
fittings
£
141,000
23,393
-
164,393
-
32,099
32,099
132,294
141,000		 Computer
equipment
£
31,405
23,416
-
54,821
15,409
13,740
29,149
25,672
15,996		 Total
£
172,405
46,809
-
219,214
15,409
45,839
61,248
157,966
156,996		 Grand Total
£
351,505
114,559
-
466,064
79,337
107,588
186,925
279,139
272,168

Page 38

Annual Report and Financial Statements for the year ended 31 December 2024

Coeliac UK

Notes to the financial statements (continued)

11 Investments - Group And Charity

Investments - Group And Charity
Investments
Unit trusts
subsidiaries
£
£
Market Value at January 2024
2
982,578
Additions
-
-
Disposals
-
-
Realised investment gains/(losses)
-
37,389
Market Value at 31 December 2024
2
1,019,967
Historical cost as at 31 December 2023
2
974,783
(Charity only)		 Total
2024
£
982,580
-
-
37,389
1,019,969
974,785
Total
2023 Restated
£
323,850
634,783
-
23,947
982,580
974,785

Holdings of more than 20%

The charitable company holds more than 20% of the share capital in the following company:

Country of Shares held
Company incorporation Class %
The Coeliac Trading Company Ltd England & Wales Ordinary 100

The principal activity of The Coeliac Trading Company Limited (Company number 02856981) is to raise funds on a commercial basis for Coeliac UK (Limited by Guarantee), a registered charity. The address of the registered office is Artisan, Hillbottom Road, High Wycombe, Buckinghamshire, HP12 4HJ.

The aggregate amount of capital and reserves and the results of this undertaking for the year ended 31 December 2022 were:

Profits to
reserves for
Capital the year
£ £
The Coeliac Trading Company Ltd 2 -

During 2024 the Trading Company proposed to donate its entire profits and reserves of £0 (2023: £123,360) to Coeliac UK. The profits are net of income and expenditure totalling £0 (2023: £590,132) and £0 (2023: £240,750) respectively.

Current asset investments and deposits held relate exclusively to cash deposit accounts amounted to £nil (2023: £nil) as shown on the balance sheet.

Page 39

Annual Report and Financial Statements for the year ended 31 December 2024

Coeliac UK

Notes to the financial statements (continued)

12 Debtors

Debtors Debtors
2024
2023
Restated
£
£
Trade debtors
174,913
142,846
Income tax and VAT recoverable
28,030
75,124
Amounts owed by group undertakings
-
-
Prepayments and accrued income
1,497,014
1,386,720
1,699,957
1,604,690
Creditors: amounts falling due within one year
2024
2023
Restated
£
£
Grants payable
713,147
541,079
Trade creditors
256,193
372,192
Other tax and social security
53,792
52,940
Accruals
240,071
307,857
Deferred income
610,694
503,204
1,873,897
1,777,272
Deferred income - Charity
At 1 January
Released in year
At 31 December
Group
Group
Membership, licencing, Lottery and sponsorship income
received in advance		 2024
2023
Restated
£
£
174,913
142,846
28,030
75,124
-
111,904
1,497,014
1,386,720
1,699,957
1,716,594
2024
2023
Restated
£
£
713,147
541,079
256,193
372,192
53,792
52,940
240,070
307,857
610,694
503,204
1,873,896
1,777,272
2024
2023
Restated
£
£
503,201
490,481
(444,002)
(467,545)
551,495
480,265
610,694
503,201
Charity
Charity
1,777,272 1,777,272
2023
Restated
£
490,481
(467,545)
480,265
503,201

13 Creditors: amounts falling due within one year

14 Provision for liabilities and charges - Group and Charity

At 1 January 2024
Charged for the year
At 31 December 2024		 £
-
(9,000)
(9,000)

The Charity moved in to new offices at the start of 2024 and has an obligation to return the premises to their original condition on expiry of the lease. The Charity is providing for the expected costs of these dilapidations equally over the lifetime of the lease.

Page 40

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2024

Notes to the financial statements (continued)

15 Designated funds - Group and Charity

Designated funds are funds earmarked by the board of Trustees for particular purposes. At the year end, the balance of designated funds were as follows:

Research Fund
Local voluntary support groups
Research (Innovate)
Research Fund
Local voluntary support groups		 Balance at
1 January 2024
12,405
80,818
93,223
Balance at
1 January 2023
2,314
10,194
85,783
98,291		 Incoming
-
4,238
4,238
Incoming
-
2,314
6,568
8,882		 Outgoing
-
(51,821)
(51,821)
Outgoing
(2,314)
(103)
(11,533)
(13,950)		 Balance at
31 December 2024
12,405
33,235
45,640
Balance at
31 December 2023
-
12,405
80,818
93,223

Research (Innovate)

Funds to be used to develop an AI solution for diagnosis and assessment of severity of pathology in small intestinal biopsies in suspected or known coeliac disease.

Research Fund

Funds to be used for funding medical research into coeliac disease and dermatitis herpetiformis, designated by the Board from unrestricted funds.

Local voluntary support groups

The collective funds held and administered by Volunteer Groups, representing their working funds.

Page 41

Annual Report and Financial Statements for the year ended 31 December 2024

Coeliac UK

Notes to the financial statements (continued)

16a Restricted funds - Group and Charity

Research Fund
Awareness Week
Membership Helpline
Pharmacy Packs
Diagnosis campaign
Gluten Ataxia
Sponsored Dissertations
16b Prior Year Restricted funds
Research Fund
Awareness Week
Care System campaigns
Membership Helpline
Diagnosis TV Advert
Diagnosis Life Channel NHS
Pharmacy Packs
Diagnosis campaign
Events for children with Coelia
Digital Campaign
Gluten Ataxia
Sponsored Dissertations
Daily newspaper advert for
Awareness Week
Events for children with
Coeliac Disease and families
Daily newspaper advert for
Awareness Week		 197,912
1,488
-
166
1,073
21,099
5,027
-
7,500
Balance B/F		 219,058
-
40,000
7
-
-
-
40,225
-
Incoming		 (225,550)
0
(55,241)
(173)
-
-
-
-
(7,500)
Outgoing		 41,298
(1,488)
22,587
-
(1,073)
(21,099)
-
(40,225)
-
-
-
-
24,782
-
-
-
-
-
(24,782)
-
-
-
-
-
Transfer of
funds
Transfer of
funds		 232,718
-
7,346
-
-
-
5,027
-
-
Balance C/F
(288,464)

(393,269)
(41)
(59,809)
(17)
-
(2,947)
(2,014)
(2)
8,150
(9)
(2,014)
(42,270)
-
Outgoing		 245,090
0
-
197,912
1,488
-
-
166
-
-
1,073
21,099
5,027
-
0
7,500
Balance C/F
566,855 161,653 (494,245) 234,265

The principal purposes for the above restricted funds were as follows:

Research

Income received to be used solely for funding medical research into coeliac disease and dermatitis herperiformis (DH).

Daily newspaper advert for Awareness Week

Donations towards an advertisement to be placed in a major national newspaper during Awareness Week to raise the profile of coeliac disease.

Awareness Week

Funds have been granted to support the Awareness week campaign of coeliac disease in support of ongoing activities regarding awareness and education on coeliac disease.

Care System campaign

Campaign to improve awareness in the care system.

Membership Helpline

Funding for ongoing costs of providing the Coeliac UK Helpline. Diagnosis TV Advert TV advertising campaign to improve diagnosis rates for coeliac disease.

Diagnosis Life Channel NHS

Advertising campaign for patients via Life Channel in GP surgeries to raise awareness of coeliac disease.

Pharmacy packs

Donations towards production of pharmacy information packs.

Diagnosis Campaign

Funds were originally granted to pay for the development of campaign materials to promote diagnosis of coeliac disease in children in 2022 in support of ongoing activities regarding awareness and education on coeliac disease. The funder has agreed that this can be used for the Awareness week and the funds have been transfered.

Events for children with coeliac disease and their families

Funds to be used by Coeliac UK for events to benefit coeliac children and their families.

Digital Campaign

Donations toward developing our digital communication materials

Gluten Ataxia

Income to fund a project to achieve an earlier diagnosis for those with Gluten Ataxia.

Sponsored Dissertations

Funds have been granted to support the award of grants to support students preparing dissertations relating to advancement in the research of coeliac disease, with the additional hope this will encourage their ongoing and longterm engagement in coeliac disease research.

Page 42

Annual Report and Financial Statements for the year ended 31 December 2024

Coeliac UK

Notes to the financial statements (continued)

17 Analysis of net assets between funds - Group

Intangible assets
Tangible assets
Investments
Intangible assets
Tangible assets
Investments
Net current assets less provisions for
liabilities and charges
Net current assets less provisions for
liabilities and charges		 Unrestricted
funds
2024
121,173
157,966
1,019,969
325,877
1,624,985
Unrestricted
funds
2023
115,172
156,996
982,580
769,472
2,024,220		 Designated
funds
2024
-
-
-
45,640
45,640
Designated
funds
2023
-
-
-
93,223
93,223		 Restricted
funds
2024
-
-
-
245,090
245,090
Restricted
funds
2023
-
-
-
234,265
234,265		 Total
2024
121,173
157,966
1,019,969
616,607
1,915,714
Total
2023
Restated
115,172
156,996
982,580
1,096,960
2,351,708

18 Lease commitments - Group

At the reporting end date the group had outstanding commitments for future minimum lease payments under noncancellable operating leases, which fall due as follows:

Within one year
Between two and five years
More than five years		 2024
2023
£
£
82,287
76,688
321,149
306,753
-
63,798
403,436
447,239
Land and buildings		 2024
2023
£
£
3,115
2,979
10,636
9,772
1,282
-
15,033
12,751
Office equipment		 2024
2023
£
£
3,115
2,979
10,636
9,772
1,282
-
15,033
12,751
Office equipment
12,751

19 Voluntary help

The charity received support from 256 volunteers in 2024 (2023: 250). The benefit of their contribution is not reflected in the financial statements.

20 Related party transactions

Coeliac UK holds 100% of the share capital of The Coeliac Trading Company Limited.Details of transactions in the year and balances at the year end are detailed in note 11.

There were no other related party transactions in the reporting period that require disclosure.

Page 43

Coeliac UK Annual Report and Financial Statements for the year ended 31 December 2024

Notes to the financial statements (continued)

21 Pension commitments

The estimated pension deficit as at 31 December 2024 is £1275 (31 December 2023: £815). This is in accordance with the most recent independent valuation performed on 30 September 2023. Under the new recovery plan, from 1 April 2023 the deficit contributions that are required from Coeliac UK are £772 a year, payable in monthly instalments of £64.32. These payments do not increase.

The deficit contributions agreed between the company and scheme at the yearend date are as follows:

----- Start of picture text -----
||| |---|---| |Year|Amount| |1|392| |2|438| |3|438| |4|109|

----- End of picture text -----

The present value of the future provision for Coeliac UK is calculated as follows:

----- Start of picture text -----
||| |---|---| |£| |Provision at the start of the period|815| |Discount factor interest expense|23| |Deficit contribution paid|(772)| |Remeasurement - impact of change in assumptions|8| |Remeasurements - amendments to the contribution schedule|1,201| |Provision at end of period 31 December 2024|1,275|

----- End of picture text -----

The current deficit of £1,275 is being paid at an immaterial amount by the charity on an annual basis, this deficit would only fall due in its entirety should the charity decide to withdraw from the scheme, the Board of Trustees currently have no such plans.

22 Reconciliation of net income/(expenditure) for the reporting period (as per the SOFA)

----- Start of picture text -----
|||| |---|---|---| |2024|2023| |Restated| |£|£| |Net (expenditure) for the reporting period (as per the SOFA)|(435,994)|(251,865)| |Adjustments for:| |Depreciation charges|107,588|66,866| |Gains on investments|(37,389)|(23,947)| |Dividends from investments|(41,836)|(24,454)| |Bank interest|(26,686)|(40,545)| |Increase in debtors|(95,269)|(596,590)| |Increase in creditors|105,626|599,440| |Other Losses|614| |Net cash used by operating activities|(423,960)|(270,481)|

----- End of picture text -----

Page 44

Annual Report and Financial Statements for the year ended 31 December 2024

Coeliac UK

Notes to the financial statements (continued)
23
Analysis of cash and cash equivalents
Cash in hand
Notice deposits (less than 3 months)
Total cash and cash equivalents
Analysis of changes in net debt
Cash
cash equivalents		 Balance B/F
240
1,269,302
1,269,542		 2024
£
106
799,440
799,545
Cash flows
(134)
(469,862)
(469,997)		 2023
£
240
1,269,302
1,269,542
Balance C/F
106
799,440
799,545

24 Contingent Liability

We have no contingent liabilities at this time

Page 45